Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.


PhRMA Statement on Sequestration of PDUFA User Fees

Washington, DC, June 10, 2013 — Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, Ph.D., has issued the following statement:

“PhRMA remains deeply concerned about the impact of sequestration on the Food and Drug Administration’s (FDA) ability to fulfill its critical public health mission by fostering timely patient access to safe and effective new medicines. Continue reading

Sequester Withholding of FDA User Fees Irks Drug and Medical Device Makers

Washington, DC, May 21, 2013Roll Call reports that, for years, makers of drugs and medical devices have paid the Food and Drug Administration (FDA) in exchange for the agency committing to certain performance goals, including evaluating submitted drugs, therapies and technologies before they may be introduced into the marketplace.  

But now, Roll Call reports, the FDA may not be able to accomplish all those goals, because some of the funds are being cut by the sequester.   Continue reading

Forbes: Legendary Drug Industry Execs Warn U.S. Research Cuts Endanger Innovation, Economy

New York, NY, March 7, 2013 — Writing in Forbes, three legendary pharmaceutical industry executives write of the important role of government funding of research and development, innovation and science and the potential ramifications of the current federal budget sequestration.

The three authors of the Forbes opinion piece are Marc Tessier-Lavigne, President, The Rockefeller University and former Chief Scientific Officer, Genentech Inc.; P. Roy Vagelos, Chairman, Regeneron Pharmaceuticals, and Retired Chairman and CEO, Merck & Co.; and Elias Zerhouni, President R&D Sanofi and former Director of the National Institutes of Health.  Continue reading

Former NIH Director: Sequester Will Be ‘Disaster for Research’

Washington, DC, February 22, 2013 — In a Washington Post interview conducted by Dylan Matthews, Dr. Elias Zerhouni sounded the alarm regarding the potential damaging impact that a federal budget sequestration could have on innovation and research in the United States.

Dr. Zerhouni led the National Institutes of Health (NIH) from 2002 to 2008 and currently is director of research and development at Sanofi, a French pharmaceutical firm.  

Asked what impact an 8.2 percent across-the-board cut would have on the NIH, Dr. Zerhouni, said, “I think the suddenness of it and the depth of it would be a disaster for research, which is not an activity that you can turn on and off from year to year.  It’s an activity that takes time.”

The most impacted, Dr. Zerhouni added “are the young, new investigator scientists, who are coming into science, and will now abandon the field of science.  There will be a generational gap created.”

Dr. Zerhouni told the Post’s Matthews, “People have crocodile tears for all the various types of cuts, but this kind of cut is damaging.  It’s not something that you can manage year to year.  It’s an investment.  They cannot go up and down with the political winds.”

To read Mr. Matthews’ full interview with Dr. Zerhouni in The Washington Post, click here.

Report: NIH Sequester Cuts Will Harm Life Sciences Jobs, Economy

Washington, DC, February 7, 2013The Hill has reported that advocates are warning that the budget sequestration will curtail $3 billion in economic activity if cuts hit the National Institutes of Health (NIH) on March 1.

Advocacy coalition United for Medical Research (UMR) released new figures that show the NIH supported more than 402,000 jobs and about $58 billion in economic output in 2012.

The NIH budget will be cut by 5.1 percent unless lawmakers act in the next month.  UMR warned that if sequestration takes effect, approximately 20,500 life science jobs would be lost along with $3 billion in economic activity.

In a statement, UMR President Carrie Wolinetz said, “We cannot allow budget cuts, such as those looming from the sequester, to undermine the biomedical research enterprise, causing the loss of jobs and prosperity, as well as setting us back at a time when we are on the cusp of exciting new advances.”

To read the complete story in The Hill, click here.